AbCellera Biologics Stock Forecast

Stock Price Forecast

According to 13 analysts polled by S&P Global, AbCellera Biologics stock has a consensus rating of "Strong Buy" and an average price target of $17.17. The average 1-year stock price forecast is 54.41% higher than the current stock price, while the lowest is $9.00 (-19.06%) and the highest is $30 (+169.78%).

Price Target: $17.17 (+54.41%)

Analyst Consensus: Strong Buy

Price Target

Chart

Target	Low	Average	Median	High
Price	$9.00	$17.17	$16	$30
Change	-19.06%	+54.41%	+43.88%	+169.78%

Analyst Ratings

The average analyst rating for AbCellera Biologics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Chart

Rating	May '26	Jun '26	Jul '26	Aug '26	Sep '26	Oct '26
Strong Buy	7	7	8	8	8	10
Buy	1	1	1	1	2	2
Hold	1	1	0	0	1	1
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	9	9	9	9	11	13

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Roger Song Jefferies	Jefferies	Buy Initiates $21	Buy	Initiates	$21	+88.85%	Oct 30, 2026
Alice Nettleton UBS	UBS	Buy Initiates $18	Buy	Initiates	$18	+61.87%	Oct 11, 2026
Brian Cheng J.P. Morgan	J.P. Morgan	Buy Initiates $17	Buy	Initiates	$17	+52.88%	Sep 29, 2026
Debanjana Chatterjee JonesTrading	JonesTrading	Buy Reiterates $13 → $25	Buy	Reiterates	$13 → $25	+124.82%	Sep 27, 2026
Andrea Newkirk Goldman Sachs	Goldman Sachs	Hold Initiates $13	Hold	Initiates	$13	+16.91%	Sep 24, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

26.37M

from 75.13M

-64.90%

from 75.13M

Revenue Next Year

28.24M

from 26.37M

7.12%

from 26.37M

EPS This Year

-0.67

from -0.49

EPS Next Year

-0.76

from -0.67

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	375.20M	485.42M	38.03M	28.83M	75.13M	26.37M
Revenue Growth	60.92%	29.38%	-92.17%	-24.17%	160.56%	-64.90%
Operating Income	204.41M	224.91M	-237.21M	-282.77M	-217.10M	-243.38M
Net Income	153.46M	158.52M	-146.40M	-162.86M	-146.41M	-207.56M
EPS	-	-	-	-	-0.49	-0.67
Free Cash Flow	-	-	-	-	-	-126.70M
No. Analysts	-	-	-	-	-	11

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Chart

Revenue	2026	2027	2028
High	43.6M
Avg	26.4M
Low	18.0M

Revenue Growth

Chart

Revenue Growth	2026	2027	2028
High	-42.0%
Avg	-64.9%
Low	-76.0%

EPS Forecast

Chart

EPS	2026	2027	2028
High	-0.63
Avg	-0.67
Low	-0.73

EPS Growth

Chart

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-